Leerink Swann Lifts Target on Amarin (AMRN) After FDA Approval
Get Alerts AMRN Hot Sheet
Price: $0.84 -2.33%
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 8 | Down: 2 | New: 35
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 8 | Down: 2 | New: 35
Join SI Premium – FREE
Leerink Swann boosted its price target on Outperform-rated Amarin Corporation (NASDAQ: AMRN) from $25 to $27 after AMR101 (Vascepa) was approved with a robust label.
"Vascepa label looks mostly as expected in our view, with full MARINE data including LDL neutrality/ApoB reduction shown and approval of 4g dose... NCE exclusivity status would be a positive, but not essential now that at least two patents will be listed in the Orange Book from day-one," the firm notes.
They also said AMRN in a solid position ahead of a potential company sale, temporary commercial partnership, or in house launch in early 2013.
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $15.32 yesterday.
"Vascepa label looks mostly as expected in our view, with full MARINE data including LDL neutrality/ApoB reduction shown and approval of 4g dose... NCE exclusivity status would be a positive, but not essential now that at least two patents will be listed in the Orange Book from day-one," the firm notes.
They also said AMRN in a solid position ahead of a potential company sale, temporary commercial partnership, or in house launch in early 2013.
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $15.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades Veradigm Inc (MDRX) to Hold
- McDonald's (MCD) PT Raised to $312 at Citi
- Guggenheim Starts EPAM Systems (EPAM) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!